Trials / Active Not Recruiting
Active Not RecruitingNCT06532331
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
A PhaseⅠStudy to Examine Tolerability and Safety of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and Safety of ONO-7475 in Combination With GnP in Patients With Metastatic Pancreatic Cancer as First-line Treatment
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 87 (estimated)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-7475 | Specified dose on specified days |
| DRUG | ONO-4538 | Specified dose on specified days |
| DRUG | Nab-paclitaxel | Specified dose on specified days |
| DRUG | Gemcitabine | Specified dose on specified days |
Timeline
- Start date
- 2023-12-06
- Primary completion
- 2027-09-30
- Completion
- 2028-03-31
- First posted
- 2024-08-01
- Last updated
- 2025-04-18
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06532331. Inclusion in this directory is not an endorsement.